

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 July 2021 (15.07.2021)



(10) International Publication Number
WO 2021/142127 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) A61K 45/00 (2006.01)
C12N 5/071 (2010.01) C12N 15/00 (2006.01)
A61K 39/395 (2006.01) C12N 5/16 (2006.01)
A61K 39/00 (2006.01) C07H 21/04 (2006.01)

(21) International Application Number:

PCT/US2021/012510

(22) International Filing Date:

07 January 2021 (07.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/958,563 08 January 2020 (08.01.2020) US

(71) Applicant: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, Texas 78701 (US).

(72) Inventor: **REZVANI, Katy**; c/o U.T.M.D. Anderson Cancer Center, Stem Cell Transplantation & Cell Therapy, 1515 Holcombe Blvd., Unit # 0065, Houston, Texas 77030 (US).

(74) Agent: **SISTRUNK, Melissa**; Norton Rose Fulbright US LLP, 1301 McKinney Suite 5100, Houston, Texas 77010 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: A METHOD OF ENGINEERING NATURAL KILLER CELLS TO TARGET CD70-POSITIVE TUMORS




FIG. 1

(57) Abstract: Embodiments of the disclosure include methods and compositions related to targeting of CD70-expressing cells with NK cells specifically engineered to bind the CD70 antigen. In particular embodiments, NK cells that are manipulated to expressing CD70-targeting engineered receptors, such as CARs, are utilized to target cancers that express CD70. In certain embodiments, vectors that express the CD70-targeting CARs also express particular a suicide gene and/or one or more particular cytokines.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*